Value2021202220232024TTMSelling/general/admin expenses92.75 M70.35 M63.58 M47.54 M51.33 MResearch & development47.96 M74.31 M2 M400 K56.04 MOperating income135.81 M144.79 M125.47 M102.69 M104.35 MNon-Operating Income, Total796 K9.61 M86.19 M45.71 M49.76 MInterest expense, net of interest capitalized195 K131 K2.66 M3.12 M2.12 MNon-Operating Income, excl. Interest Expenses308 K8.06 M83.34 M42.11 M48.5 MUnusual income/expense293 K1.41 M189 K484 K-861 KPretax income136.6 M135.18 M39.29 M148.41 M154.11 MEquity in earnings58.55 M16.01 M3.59 M2 M0Taxes3.99 M6.23 M1.02 M356 K535 KNon-controlling/minority interest6.44 M5.03 M3.67 M780 K108 KAfter tax other income/expense———-2.1 M—Net income before discontinued operations167.81 M152.38 M40.22 M149.27 M154.19 MDiscontinued operations—————Net income167.81 M152.38 M40.22 M149.27 M154.19 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders167.81 M152.38 M40.22 M149.27 M154.19 MBasic earnings per share (Basic EPS)—-0.98-0.25-0.93-0.81Diluted earnings per share (Diluted EPS)—-0.98-0.25-0.93-0.81Average basic shares outstanding—155.72 M158.83 M160.16 M750.6 MDiluted shares outstanding—155.72 M158.83 M160.16 M750.6 MEBITDA—————EBIT—————Cost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)47 K168 K319 K473 K901 K
AtaiBeckley Inc
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.